Skip to content
Arrowhead Pharmaceuticals
-
Madrigal expands MASH pipeline with US$1B licensing deal for Arrowhead’s siRNA therapy
Under the agreement, Madrigal will take over the development, manufacturing, and commercialisation of Arrowhead’s investigational therapy, ARO-PNPLA3.